Corcept Therapeutics Incorporated Stock Today
| CORT Stock | USD 23.15 0.36 1.53% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Corcept Therapeutics is selling for under 23.15 as of the 16th of April 2024; that is -1.53 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 22.91. Corcept Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Corcept Therapeutics Incorporated are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of March 2024 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of April 2004 | Category Healthcare | Classification Health Care |
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. The company has 103.84 M outstanding shares of which 21.33 M shares are currently shorted by private and institutional investors with about 23.77 trading days to cover. More on Corcept Therapeutics Incorporated
Moving together with Corcept Stock
| 0.61 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Corcept Stock
| 0.41 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 1st of May 2024
Corcept Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Corcept Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Corcept Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Joseph Belanoff | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, ARCA Biotechnology, NASDAQ Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Corcept Therapeutics report their recommendations after researching Corcept Therapeutics' financial statements, talking to executives and customers, or listening in on Corcept Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Corcept Therapeutics. The Corcept consensus assessment is calculated by taking the average forecast from all of the analysts covering Corcept Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Corcept Therapeutics' liquidity, profitability, solvency, and operating efficiency, Corcept Therapeutics Incorporated is doing better financially then in previous quarter. It has a moderate probability of reporting better financial numbers in May. Financial strength of Corcept Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corcept Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Corcept Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corcept Therapeutics' financial leverage. It provides some insight into what part of Corcept Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corcept Therapeutics Incorporated (CORT) is traded on NASDAQ Exchange in USA. It is located in 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 and employs 352 people. Corcept Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corcept Therapeutics's market, we take the total number of its shares issued and multiply it by Corcept Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Corcept Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 103.84 M outstanding shares of which 21.33 M shares are currently shorted by private and institutional investors with about 23.77 trading days to cover.
Corcept Therapeutics Incorporated currently holds about 370.09 M in cash with 127.04 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45.
Check Corcept Therapeutics Probability Of Bankruptcy
Ownership AllocationCorcept Therapeutics holds a total of 103.84 Million outstanding shares. The majority of Corcept Therapeutics Incorporated outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corcept Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corcept Therapeutics. Please pay attention to any change in the institutional holdings of Corcept Therapeutics Incorporated as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Corcept Ownership Details
Corcept Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Corcept Therapeutics jumping above the current price in 90 days from now is about 67.44%. The Corcept Therapeutics Incorporated probability density function shows the probability of Corcept Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8324 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Corcept Therapeutics will likely underperform. Additionally, corcept Therapeutics Incorporated has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Corcept Therapeutics to move above the current price in 90 days from now is about 67.44 (This Corcept Therapeutics Incorporated probability density function shows the probability of Corcept Stock to fall within a particular range of prices over 90 days) .
Corcept Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Corcept Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corcept Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corcept Therapeutics' value.| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2023-09-30 | 1.5 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | |
| Arrowstreet Capital Limited Partnership | 2023-12-31 | 1.1 M | |
| Northern Trust Corp | 2023-12-31 | 1.1 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 900.4 K | |
| Man Group Plc | 2023-12-31 | 826.1 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 772.8 K | |
| Norges Bank | 2023-12-31 | 757.5 K | |
| Blackrock Inc | 2023-12-31 | 16.4 M | |
| Vanguard Group Inc | 2023-12-31 | 9.5 M |
Corcept Therapeutics Historical Income Statement
Corcept Therapeutics Incorporated Income Statement is one of the three primary financial statements used for reporting Corcept's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Corcept Therapeutics revenue and expense. Corcept Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Corcept Therapeutics' Net Income is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 19.3 M in 2024, whereas Reconciled Depreciation is likely to drop slightly above 2.1 M in 2024. View More FundamentalsCorcept Stock Against Markets
Picking the right benchmark for Corcept Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Corcept Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Corcept Therapeutics is critical whether you are bullish or bearish towards Corcept Therapeutics Incorporated at a given time. Please also check how Corcept Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Corcept Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Corcept Therapeutics Corporate Directors
Corcept Therapeutics corporate directors refer to members of a Corcept Therapeutics board of directors. The board of directors generally takes responsibility for the Corcept Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Corcept Therapeutics' board members must vote for the resolution. The Corcept Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Mahoney | Independent Director | Profile | |
| Renee Gala | Director | Profile | |
| Len Baker | Independent Director | Profile | |
| George Baker | Independent Director | Profile |
How to buy Corcept Stock?
Before investing in Corcept Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Corcept Therapeutics. To buy Corcept Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Corcept Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Corcept Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Corcept Therapeutics Incorporated stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Corcept Therapeutics Incorporated stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Corcept Therapeutics Incorporated, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Corcept Stock please use our How to Invest in Corcept Therapeutics guide.
Already Invested in Corcept Therapeutics Incorporated?
The danger of trading Corcept Therapeutics Incorporated is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Corcept Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Corcept Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Corcept Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Corcept Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corcept Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corcept Therapeutics Incorporated Stock. Highlighted below are key reports to facilitate an investment decision about Corcept Therapeutics Incorporated Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Corcept Stock analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.995 | Earnings Share 0.94 | Revenue Per Share 4.658 | Quarterly Revenue Growth 0.314 | Return On Assets 0.1113 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.